RxDoctor Payments Data

Robert Thomas, PA

Physician Assistant · Vineland, NJNPI 1053414110

Payments from drug & device makers

$5,537in general payments, 2019–2025

Across 361 payments — averaging $15.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novartis$399
  • Regeneron Healthcare Solutions, Inc.$364
  • Lilly USA, LLC$330
  • LEO Pharma Inc.$302
  • Pfizer$284
  • plus $2K from 19 others

What the payments were for

  • Food & beverage$5,38297%
  • Education$1553%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,537 in reported general payments places this provider in the 95th percentile of 2,726 physician assistant providers in New Jersey.

See all physician assistant providers in New Jersey

Medicare billing

Part B allowed, 2024
$58,974
Medicare patients
293
Services billed
830

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab84$320,372
Humira(Cf) PenAdalimumab17$174,432
Humira PenAdalimumab14$150,750
OlumiantBaricitinib29$108,458
OpzeluraRuxolitinib Phosphate15$30,312
Ammonium Lactate521$11,300
Fluocinonide149$9,615
Gentamicin Sulfate192$8,480
Ketoconazole405$6,964
Calcipotriene35$6,954
Tacrolimus29$5,307
Mometasone Furoate244$5,281
Clobetasol Propionate100$5,022
Clindamycin Phosphate107$4,163
CiclopiroxCiclopirox Olamine126$4,131

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCOlumiant$330$108,45829 claims
Incyte CorporationOpzelura$30$30,31215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,726 physician assistant providers in New Jersey.

Other physician assistant in Vineland

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →